187420.KQ GenoFocus Inc

Basic Materials Chemicals KOSDAQ
2,360 KRW
Close of Oct 30, 2026
1,323 3,680
Market cap
KRW 77.0B
P/E
7.9x
P/B
1.43x
ROE
14.8%
Dividend yield
-
Fundamental score
2.7/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 187420.KQ undervalued?

Graham number
Price2,360
Graham value3,325
Discount29.0%

187420.KQ trades 29.0% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GenoFocus Inc fundamental analysis

13 of 22 checks passed

ROE 1/2

Moderate return on equity (14.8%), between 10% and 20%.

ROA 1/1

Return on assets (5.8%) is above the industry median (4.7%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (219.0%) is above the industry median (-16.9%).

Revenue Growth 2/2

Revenue grew 16.0% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (10.5%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 0/1

EBIT is 1.8x against interest expense, below 5x.

PE vs Market 1/1

PE (7.9x) is below the market median (11.3x).

PE vs Industry 1/1

PE (7.9x) is below the industry median (9.1x).

PBV 0/1

Price to book (1.4x) is above the industry median (0.6x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 11.3, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

GenoFocus Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GenoFocus Inc

HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet …

Full company profile